

MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS

Regd. Office: 4th Floor, Sambava Chambers, Sir P. M. Road, Fort, Mumbai - 400 001.

Tel.: 00 91 (22) 4082 8100 | Fax: 00 91 (22) 4082 8181 | E-mail: info@amphray.com

Corporate Identity Number: L24249MH1972PLC015544

Ref No: TPL PP 0924 2018

3rd November, 2018

To

Corporate Relationship Department

Bombay Stock Exchange Limited

P. J. Towers, Dalal Street, Fort, Mumbai - 400 001

Fax No.: 022 - 22722037 / 2039 / 2041 / 2061 / 3121 / 3719

<u>Sub: Outcome of the Board - Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulation, 2015</u>

Ref: Security Code No.512101 - ISIN No.: INE 331 E 01013

Dear Sir / Madam,

Pursuant to Notice of Board meeting dated 13<sup>th</sup> October, 2018 the Board meeting was held on today Saturday, 3<sup>rd</sup> November, 2018 at 2.00 p.m. at 4<sup>th</sup> Floor, Sambava Chambers, Sir P. M. Road, Fort, Mumbai: 400001 and has approved the following:

- The Board approved the Unaudited Financial Results for the quarter and half year ended on 30<sup>th</sup> September, 2018 in accordance with Indian Accounting Standards (Ind AS) as per Companies (Indian Accounting Standards) Rules, 2015, as reviewed by the Audit Committee in accordance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.
- The Board noted and took on records the Limited Review Report of Statutory Auditors of the Company for the quarter and half year ended 30<sup>th</sup> September, 2018, as placed before the Board.
- 3. The Board took note on Register of contracts with related party and contracts and Bodies etc. in which directors are interested [Pursuant to section 189(1) and rule 16(1)] [Form MBP-4]. (A) Contract or agreements with any related party under section 188 or in which any director is concerned or interested under sub-section (2) of section 184 for the quarter ended 30th September, 2018. (B) Name of the bodies corporate, firms or other association of individuals as mentioned under sub-section (1) of section 184, in which any director is having any concern or interest for the quarter

onded 30th September, 2018.

Page 1 of 2



MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS

Regd. Office: 4th Floor, Sambava Chambers, Sir P. M. Road, Fort, Mumbai - 400 001. Tel.: 00 91 (22) 4082 8100 | Fax: 00 91 (22) 4082 8181 | E-mail: info@amphray.com

Corporate Identity Number: L24249MH1972PLC015544

 Re-constituted of Stakeholders Relationship Committee, which shall comprises of the following member:

Name	Status	Category
Mr. Sunil S. Jhunjhunwala	Chairman	Non - Executive - Independent Director
Mr. Girish Kumar Pungalia	Member	Non - Executive - Independent Director
Mrs. Grace R. Deora	Member	Non - Executive - Director

- 5. Take notes on the compliance for the quarter and half year ended 30th September, 2018
- 6. Board Meeting commenced at 2.00 p.m. and concluded at 5.25 p.m.

You are requested to take note of the same.

Thanking you,

Yours faithfully,

For TRIOCHEM PRODUCTS LIMITED

RAMU S. DEORA

DIRECTOR

DIN: 00312369

Place: Mumbai



# Kanu Doshi Associates LLP

Chartered Accountants

Mumbai Address: 203, The Summit, Hanurian Road, Western Express Highway, Vile Parle (E), Mumbai - 400 057 T: 022-2615 0100 / 111 / 112 • F: 022 2615 0113

Pune Address : 123, Sohrab Hall, 21 Sassoon Road, Opp. Jehangir Hospital, Pune - 411001 • T : 020 4906 7177

E:info@kdg.co.in • W: www.kdg.co.in

### Limited Review Report

To.

The Board of Directors of TRIOCHEM PRODUCTS LIMITED

- 1. We have reviewed the accompanying statement of unaudited financial results of TRIOCHEM PRODUCTS LIMITED ("Company") for the quarter and six months ended September 30, 2018 and the statements of assets and liabilities on that date together with notes thereon (the 'Statement') attached herewith, being submitted by the Company pursuant to requirement of Regulation 33 of the securities and Exchange Board of India (SEBI) (Listing Obligation and Disclosure Requirements) Regulations, 2015, as modified by the Circular no. CIR/CFD/FAC/62/2016 dated 5<sup>th</sup> July, 2016 (the Regulations).
- 2. This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laic down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
- 3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information performed by Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results has not been prepared in accordance with applicable Indian Accounting Standards specified under section 133 of the Companies Act, 2013 read with relevant rules there under and other recognized accounting practices and policies and has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

DOSHI AS

For Kanu Doshi Associates LLP

Chartered Accountants

Firm Registration No: 104746W/W100096

Kunal Vakharia

Partner

Membership No.: 148916

Place: Mumbai

Date: November 03, 2018



# MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS

Regd. Office : 4th Floor, Sambava Chambers, Sir P. M. Road, Fort, Mumbai - 400 001. Tel. : 00 91 (22) 4082 8100 | Fax : 00 91 (22) 4082 8181 | E-mail : info@amphray.com

Corporate Identity Number: L24249MH1972PLC015544


# TRIOCHEM PRODUCTS LIMITED

Registered Office: Sambava Chamber, 4th Floor, Sir P M Road, Fort, Mumbai - 400 001.

Website: www.triochemproducts.com CIN: L24249MH1972PLC015544

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2018

Sr.	Particulars		Overton Ended		(Rs in Lakh) Except EPS			
No.	ratticulats	Quarter Ended			Half Year Ended		Year Ended	
110.		30-Sep-18	30-Jun-18	30-Sep-17	30-Sep-18	30-Sep-17	31-Mar-18	
1	Income	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	
1		20.07	(70.70	2///1	<b>=00.</b> ((	. /**		
	(a) Revenue from Operations	29.94	670.72	346.61	700.66	1,652.11	3,552.4	
	(b) Other Income	1.85	1.02	4.37	2.87	19.58	41.0	
	Total Income From Operations	31.79	671.74	350.98	703.53	1,671.69	3,593.4	
2	Expenses							
	(a) Cost of Materials Consumed	-9.69	609.25	465.69	599.56	968.39	2,252.4	
	(b) Purchase of stock in trade	•	6.00	•	6.00	579.50	623.3	
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-4.84	-92.47	-175.07	-97.31	-184.32	2.2	
	(d) Excise duty on sale of goods					53.40	53.4	
	(e) Employees Benefit Expenses	16.68	17.81	19.24	34.49	36.38	73.0	
	(f) Finance Costs	14.17	11.66	12.38	25.83	21.37	38.4	
	(g) Depreciation and Amortisation Expenses	5.16	5.11	6.17	10.27	12.13	24.7	
	(h) Other Expenditure	33.53	38.58	35.72	72.11	69.30	168.8	
	Total expenses	55.01	595.94	364.13	650.95	1,556.15	3,236.4	
6	Profit before exceptional items and tax	-23.22	75.80	-13.15	52.58	115.54	356.9	
	Exceptional items							
;	Profit/ (Loss) before tax	-23.22	75.80	-13.15	52.58	115.54	356.9	
5	Tax Expense							
	(a) Current tax	-6.42	22.17	-4.01	15.75	32.69	104.6	
	(b) Deferred tax	-1.46	-2.86	-0.15	-4.32	-1.19	-3.1	
	Total tax expenses	-7.88	19.31	-4.16	11.43	31.50	101.4	
- 1	Net Profit/ (Loss) for the period	-15.34	56.49	-8.99	41.15	84.04	255.50	
- 1	Other Comprehensive Income (Net of Taxes)		, , ,					
	(A)(i). Items that will be reclassified to profit or loss						v	
	(ii). Income tax relating to items that will be reclassified to profit or loss			-			-	
	(B)(i). Item that will not be reclassified to profit or loss	-0.57	-0.38	0.15	-0.95	0.31	-0.3	
	(ii). Income tax relating to items that will not be reclassified to profit or loss	0.15	0.10	-0.04	0.25	-0.08	0.1	
- 1	Total other Comprehensive Income (net of taxes)	-0.42	-0.28	0.11	-0.70	0.23	-0.2	
- 1	Total Comprehensive Income for the period	-15.76	56.21	-8.88	40.45	84.27	255.2	
	Paid-up equity share capital (Face Value of ₹ 10/- per share)	24.50	24.50	24.50	24.50	24.50	24.5	
	Other equity as per Balance Sheet of previous accounting year						778.7	
2	Earnings per equity share (EPS) (of Rs. 10/- each) (not annualised)						,,30	
-	Basic / Diluted EPS (in Rs.)	-6.26	23.06	-3.67	16.80	34.30	104.2	



CHARTER ACCOUNTANTS

Factory: Plot No. 10/2, MIDC Industrial Area, Chikhloli, Ambernath (West), Dist. Thane, PIN - 421 505 MAHARASHTRA.

Tel.: 0251-268 2191 \* 268 2711 | Fax: 0251-268 2192



# MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS

Regd. Office: 4th Floor, Sambava Chambers, Sir P. M. Road, Fort, Mumbai - 400 001. Tel.: 00 91 (22) 4082 8100 | Fax: 00 91 (22) 4082 8181 | E-mail: info@amphray.com

Corporate Identity Number: L24249MH1972PLC015544

Disclosure of Standalone Statement of Assets and Liabilities as per Clause 41(1) (ea) of the listing agreement for the half year ended 30th September, 2018 STATEMENT OF ASSETS AND LIABILITIES AS AT 30TH SEPTEMBER, 2018

	Particulars	As at	As at
		30-Sep-18	31-Mar-18
		(Unaudited)	(Audited)
A	ASSETS		
1	Non- Current Assets		
	(a) Property, plant and equipment	122.82	132.90
	(b) Investment property	8.74	8.90
	(c) Other intangible assets	0.02	0.0
	(d) Financial assets		
	(i) Other financial assets	7.63	7.63
	(e) Other non current Assets	24.82	35.3
	Sub Total - Non- Current Assets	164.03	184.94
	Current Assets		
	(a) Inventories	1,140.94	822.53
	(b) Financial Assets		
	(i) Trade receivable	45.92	
	(ii) Cash and cash equivalents	7.51	91.9
	(iii) Other financial assets	0.28	0.50
	(c) Other tax assets (net)	1.80	
	(c) Other current assets	117.80	79.93
	Sub Total - Current Assets	1,314.25	994.93
	TOTAL ASSETS	1,478.28	1,179.87
В	EQUITY AND LIABILITIES		
	Equity		
	(a) Equity share capital	24.50	24.50
	(b) Other equity	819.20	778.70
	Sub Total - Shareholder's fund	843.70	803.26
	Liabilities		
	(a) Non Current Liabilities		
	(a) Deferred tax liabilities (Net)	8.36	12.92
	(b) Current Liabilities		
	(a) Financial liabilities		
	(i) Borrowing	563.66	228.05
	(ii) Trade payables	20.83	71.96
	(b) Other financial liabilities	22.59	
	(c) Other current liabilities	2.56	0.89
	(d) Provisions	16.58	16.22
	(e) Current tax liabilities (Net)		46.57
	Sub Total - Liabilities	634.58	376.61
	TOTAL EQUITY AND LIABILITIES	1,478.28	1,179.87

### Notes:

The Company operates in single segment only, i.e. chemical and pharmaceuticals.

Cost of Materials Consumed includes rate difference debit notes pertaining to previous quarter amounted to Rs.56.71 lakhs

The above unaudited financial results of the Company as reviewed and recommended by the Audit Committee has been approved by the Board of Directors in its meeting held on 3rd November, 2018 as per Regulation 33 of SEBI (listing Obligations and Disclosure Regulations, 2015. The statutory auditors of the company has carried out a limited review of aforesaid results.

> SRED ACCOU

Factory : Plot No. 10/2, MIDC Industrial Area, Chikhloli, Ambernath (West), Dist. Thane, PIN - 421 505 MAHARASHTRA.



# MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS

Regd. Office: 4th Floor, Sambava Chambers, Sir P. M. Road, Fort, Mumbai - 400 001.
Tel.: 00 91 (22) 4082 8100 | Fax: 00 91 (22) 4082 8181 | E-mail: info@amphray.com

Corporate Identity Number: L24249MH1972PLC015544

Consequent to introduction of Goods and Services Tax (GST) w.e.f. 1st July, 2017. The excise duty / VAT etc. has been subsumed in GST. In accordance with IND AS 18 on Revenue and Schedule III of the Companies Act, 2013, Revenue from operations are required to be shown net off GST and inclusive of Excise Duty. Accordingly figures of revenue from operation for the half year ended 30th September, 2018 are not comparable with previous half year ended 30th September, 2017.

5) Corresponding figures of the previous quarter/half year/year have been regrouped, recated and reclassified to make them comparable wherever necessary.

FOR TRIOCHEM PRODUCTS LIMITED

Place: Mumbai

Dated: 3rd November, 2018



RAMU S. DEORA

DIRECTOR & CEO DIN: 00312369



6



# MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS

Regd. Office: 4th Floor, Sambava Chambers, Sir P. M. Road, Fort, Mumbai - 400 001. Tel.: 00 91 (22) 4082 8100 | Fax: 00 91 (22) 4082 8181 | E-mail: info@amphray.com

Corporate Identity Number: L24249MH1972PLC015544

### TRIOCHEM PRODUCTS LIMITED

Registered Office: Sambava Chamber, 4th Floor, Sir P M Road, Fort, Mumbai - 400 001.

Website: www.triochemproducts.com CIN: L24249MH1972PLC015544

EXTRACT OF STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2018

Sr.	Particulars	Quarter Ended			Half Year Ended		Year Ended	
No.		30-Sep-18 (Unaudited)	30-Jun-18 (Unaudited)	30-Sep-17 (Unaudited)	30-Sep-18 (Unaudited)	30-Sep-17 (Unaudited)	31-Mar-18 (Audited)	
1	Total revenue from operations	31.79	671.74	350.98	703.53	1,671.69	3,593.46	
2	Net Profit / (Loss) for the period (Before taxe, Exceptional and / or	(23.22)	75.80	(13.15)	52.58	115.54	356.97	
	Extraordinary items)	~						
3	Net Profit / (Loss) for the period before tax (After Exceptional and /	(23.22)	75.80	(13.15)	52.58	115.54	356.97	
	or Extraordinary items)	71.						
4	Net Profit / (Loss) for the period after tax (After Exceptional and /	(15.34)	56.49	(8.99)	41.15	84.04	255.50	
	or Extraordinary items)							
5	Total Comprehensive Income for the period [Comprising Profit /	(0.42)	(0.28)	0.11	(0.70)	0.23	(0.28)	
	(Loss) for the period (after tax) and Other Comprehensive Income							
	(after tax)]							
6	Equity share capital (Face value of Rs.10/- per share)	24.50	24.50	24.50	24.50	24.50	24.50	
7	Reserve (Excluding Revaluation Reserves as shown in the Audited						778.76	
	Balance Sheet of the previous year)							
8	Earnings per equity share (EPS) (of Rs. 10/- each) (for continuing							
	and discontinued operations)							
	a) Baisc earning per share (not annualized)	-6.26	23.06	-3.67	16.80	34.30	104.29	
	b) Diluted earning per share (not ammualized)	-6.26	23.06	-3.67	16.80	34.30	104.29	

### Notes

- The Company operates in single segment only, i.e. chemical and pharmaceuticals.
- The above unaudited financial results of the Company as reviewed and recommended by the Audit Committee has been approved by the Board of Directors in its meeting held on 3rd November, 2018 as per Regulation 33 of SEBI (listing Obligations and Disclosure Requirements) Regulations, 2015. The statutory auditors of the company has caried out a limited review of aforesaid results.
- Consequent to introduction of Goods and Services Tax (GST) w.e.f. 1st July, 2017. The excise duty / VAT etc. has been subsumed in GST. In accordance with IND AS 18 on Revenue and Schedule III of the Companies Act, 2013, Revenue from operations are required to be shown net off GST and inclusive of Excise Duty. Accordingly figures of revenue from operation for the half year ended 30th September, 2018 are not comparable with previous half year ended 30th September, 2017.
- Corresponding figures of the previous quarter/half year/year have been regrouped, recated and reclassified to make them comparable wherever necessary.
- The above is an extract of the detailed format of quarterly and half year ended financial results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulation, 2015. The full format of the quarterly and half year ened financial results are available on the on the Stock Exchange and the Company namely www.bseindia.com and www.triochemproducts.com

FOR TRIOCHEM PRODUCTS LIMITED

RAMU S. DEORA

DIRECTOR & CEO

DIN: 00312369

Dated: 3rd November, 2018

Place: Mumbai

Factory: Plot No. 10/2, MIDC Industrial Area, Chikhloli, Ambernath (West), Dist. Thane, PIN - 421 505 MAHARASHTRA.

Tel.: 0251-268 2191 \* 268 2711 | Fax: 0251-268 2192